X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (32410) 32410
Magazine Article (59) 59
Newsletter (31) 31
Book Chapter (12) 12
Publication (11) 11
Newspaper Article (10) 10
Book / eBook (5) 5
Conference Proceeding (5) 5
Dissertation (4) 4
Book Review (3) 3
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29621) 29621
female (20051) 20051
middle aged (17246) 17246
antineoplastic combined chemotherapy protocols - therapeutic use (17156) 17156
male (16360) 16360
fluorouracil - administration & dosage (16039) 16039
aged (14956) 14956
oncology (14546) 14546
adult (12641) 12641
fluorouracil - therapeutic use (11117) 11117
chemotherapy (9883) 9883
fluorouracil (8836) 8836
cancer (7516) 7516
treatment outcome (6921) 6921
5-fluorouracil (5512) 5512
antineoplastic combined chemotherapy protocols - adverse effects (5062) 5062
combined modality therapy (5038) 5038
colorectal neoplasms - drug therapy (4820) 4820
cisplatin - administration & dosage (4795) 4795
fluorouracil - adverse effects (4309) 4309
neoplasm staging (4250) 4250
breast neoplasms - drug therapy (4093) 4093
prognosis (3971) 3971
leucovorin - administration & dosage (3967) 3967
colorectal cancer (3917) 3917
chemotherapy, adjuvant (3892) 3892
aged, 80 and over (3860) 3860
antineoplastic agents - therapeutic use (3704) 3704
deoxycytidine - analogs & derivatives (3622) 3622
survival rate (3556) 3556
adenocarcinoma - drug therapy (3502) 3502
surgery (3454) 3454
animals (3411) 3411
drug administration schedule (3367) 3367
disease-free survival (3366) 3366
capecitabine (3303) 3303
leucovorin (3211) 3211
therapy (3178) 3178
colorectal neoplasms - pathology (3177) 3177
antimetabolites, antineoplastic - therapeutic use (3078) 3078
retrospective studies (3067) 3067
carcinoma (3056) 3056
fluorouracil - analogs & derivatives (3018) 3018
oxaliplatin (2978) 2978
antineoplastic combined chemotherapy protocols - administration & dosage (2915) 2915
survival analysis (2909) 2909
care and treatment (2871) 2871
survival (2790) 2790
follow-up studies (2782) 2782
neoplasm metastasis (2768) 2768
cisplatin (2712) 2712
pharmacology & pharmacy (2691) 2691
radiotherapy (2631) 2631
stomach neoplasms - drug therapy (2615) 2615
organoplatinum compounds - administration & dosage (2614) 2614
camptothecin - analogs & derivatives (2562) 2562
cyclophosphamide - administration & dosage (2421) 2421
medicine & public health (2415) 2415
deoxycytidine - administration & dosage (2370) 2370
metastasis (2306) 2306
liver neoplasms - secondary (2276) 2276
liver neoplasms - drug therapy (2262) 2262
trial (2192) 2192
carcinoma, squamous cell - drug therapy (2184) 2184
colonic neoplasms - drug therapy (2131) 2131
research (2079) 2079
mice (2068) 2068
time factors (2014) 2014
prospective studies (2000) 2000
methotrexate - administration & dosage (1935) 1935
irinotecan (1931) 1931
breast neoplasms - pathology (1873) 1873
doxorubicin - administration & dosage (1840) 1840
breast cancer (1836) 1836
analysis (1818) 1818
fluorouracil - pharmacology (1801) 1801
camptothecin - administration & dosage (1796) 1796
leucovorin - therapeutic use (1795) 1795
antimetabolites, antineoplastic - administration & dosage (1722) 1722
bevacizumab (1718) 1718
lymphatic metastasis (1710) 1710
neoadjuvant therapy (1602) 1602
clinical trials as topic (1573) 1573
tumors (1566) 1566
drug therapy, combination (1564) 1564
adenocarcinoma - pathology (1543) 1543
combination (1532) 1532
1st-line treatment (1523) 1523
infusions, intravenous (1502) 1502
dose-response relationship, drug (1493) 1493
deoxycytidine - therapeutic use (1462) 1462
chemoradiotherapy (1455) 1455
stomach neoplasms - pathology (1442) 1442
randomized-trial (1434) 1434
antineoplastic agents - administration & dosage (1430) 1430
health aspects (1426) 1426
rectal neoplasms - drug therapy (1425) 1425
drug therapy (1424) 1424
adenocarcinoma (1417) 1417
organoplatinum compounds - therapeutic use (1386) 1386
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28929) 28929
Japanese (2399) 2399
German (658) 658
French (587) 587
Chinese (450) 450
Russian (344) 344
Italian (209) 209
Spanish (120) 120
Polish (64) 64
Hungarian (35) 35
Portuguese (35) 35
Korean (27) 27
Danish (21) 21
Dutch (21) 21
Czech (18) 18
Hebrew (18) 18
Norwegian (18) 18
Ukrainian (10) 10
Bulgarian (9) 9
Romanian (9) 9
Slovak (8) 8
Swedish (7) 7
Serbian (5) 5
Croatian (4) 4
Lithuanian (3) 3
Arabic (2) 2
Finnish (2) 2
Afrikaans (1) 1
Icelandic (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
.... This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
...). Randomisation was not blinded, and was stratified by technical resectability and number of metastases, use of PET staging, and EGFR expression... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | GUIDELINES | OXALIPLATIN | FLUOROURACIL | COMBINATION | HEPATIC RESECTION | CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 1, pp. 113 - 119
Journal Article
13.